Compare CPAC & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPAC | MGTX |
|---|---|---|
| Founded | 1949 | 2015 |
| Country | Peru | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 848.5M | 909.1M |
| IPO Year | 2003 | 2018 |
| Metric | CPAC | MGTX |
|---|---|---|
| Price | $10.62 | $10.66 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $12.90 | ★ $24.57 |
| AVG Volume (30 Days) | 16.7K | ★ 617.7K |
| Earning Date | 04-24-2026 | 05-12-2026 |
| Dividend Yield | ★ 5.23% | N/A |
| EPS Growth | N/A | ★ 33.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,391,000.00 |
| Revenue This Year | $4.49 | $141.38 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.78 | ★ N/A |
| Revenue Growth | N/A | ★ 144.57 |
| 52 Week Low | $5.66 | $5.14 |
| 52 Week High | $11.50 | $11.85 |
| Indicator | CPAC | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.94 | 64.46 |
| Support Level | $10.32 | $7.11 |
| Resistance Level | $10.88 | $11.85 |
| Average True Range (ATR) | 0.20 | 0.43 |
| MACD | -0.02 | 0.05 |
| Stochastic Oscillator | 28.95 | 97.71 |
Cementos Pacasmayo SAA is a Peruvian cement company that produces, distributes, and sells cement and cement-related materials, such as concrete blocks and ready-mix concrete. The company's products are used in construction. It also produces and sells quicklime for use in mining operations. The company sells its products mainly in the northern part of Peru. It owns three cement production and transportation facilities. Its flagship Pacasmayo facility is located in the northwest region of Peru, while its new cement plant in Piura and smaller Rioja facility are located in the northeast region of Peru.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.